Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9323MR)

This product GTTS-WQ9323MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9323MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4370MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ12228MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ3625MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ13152MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ14018MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ12924MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ7623MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ8932MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW